Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

• Published in: Journal of neurology Vol. 267; no. 1; pp. 125 - 131
• Main Authors: Morales, Fabian Sierra, Koralnik, Igor J., Gautam, Shiva, Samaan, Soleil, Sloane, Jacob A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2020; Springer Nature B.V
• Subjects: Adult; Age; Age Factors; Aged; Body Mass Index; Carbamazepine; CD4 antigen; CD8 antigen; Demography; Dimethyl Fumarate - adverse effects; Ethnicity; European Continental Ancestry Group - ethnology; Female; Humans; Immunomodulators; Immunosuppressive Agents - adverse effects; Lymphocyte Count; Lymphocytes; Lymphocytes T; Lymphopenia; Lymphopenia - chemically induced; Male; Medicine; Medicine & Public Health; Middle Aged; Minority & ethnic groups; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - ethnology; Narcotics; Neurology; Neuroradiology; Neurosciences; Opioids; Original Communication; Retrospective Studies; Risk Factors; Smoking; Steroid hormones; Tobacco; Vitamin D; Lymphopenia; Multiple sclerosis; Dimethyl fumarate

Objectives To identify risk factors for DMF-induced lymphopenia and characterize its impact on T lymphocyte subsets in MS patients. Methods We performed a retrospective analysis of 194 RRMS patients treated with DMF at the Beth Israel Deaconess Medical Center (BIDMC) over a median of 17 months. We r...